Ophthalmology Specialist Harrow Revenue Grows by 84% in Q4 - A Game Changer

Harrow (HROW) is a pharmaceutical company specialized in ophthalmology based in the USA. The stock was a high flyer last year. The company focuses on the development and marketing of ophthalmic pharmaceutical products for the US market. On Thursday evening (March 27), Harrow reported Q4 numbers that impressed. The company recorded a record revenue of $66.8 million in the quarter – an 84% increase compared to the previous year. Analysts had expected around $61 million. The growth was primarily driven by a demand increase of over 40% for IHEEZO...